More than half of double-vaccinated blood cancer patients are left without effective protection against coronavirus, new research has found.
Data from a trial published in Cancer Cell shows 57% of blood cancer patients failed to develop the effective antibodies for an immune response to the virus after their second jab.
The study authors argued for "protective measures" such as mandatory mask-wearing and social distancing to continue, and for those affected to receive their additional jab, following the trial.
The trial, led by King's College London and the Francis Crick Institute, with support from Cancer Research UK, assessed 159 people at Guy's and St Thomas' NHS Foundation Trust, including 72 solid cancer and 56 blood cancer patients